Ask AI
ProCE Banner Activity

CELMoDs: Answers to Your Questions on Immune-Based Combinations and Treatment Duration in Multiple Myeloma

Clinical Thought

As CELMoDs move from investigational promise toward projected roles in clinical practice in an increasingly complex multiple myeloma treatment landscape, healthcare professionals face questions about where these agents may fit among immune-based strategies. This activity examines emerging evidence and expert perspectives on iberdomide- and mezigdomide-based approaches, including their potential use in combination regimens for patients with high-risk features or extramedullary disease, sequencing considerations after or alongside BCMA- and GPRC5D-targeted therapies, and the evolving role of MRD negativity in guiding treatment duration decisions.

Released: July 23, 2026

Continue Activity View Activity

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from Bristol Myers Squibb.

Bristol Myers Squibb

Target Audience

This program is intended for hematologists, oncologists, and other healthcare professionals who care for patients with multiple myeloma.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Describe the mechanistic and clinical rationales for combining novel agents with protease inhibitors, anti-BCMA T-cell engagers, and other standard antimyeloma therapies

  • Assess how emerging data for novel agent-based regimens could impact near-future treatment options for patients with newly diagnosed through heavily pretreated multiple myeloma

  • Identify patients with multiple myeloma who are likely to benefit from novel agent-based therapies under clinical trial investigation

Faculty Disclosure

Primary Author

Francesca Gay, MD, PhD: consultant/advisor/speaker: Amgen, AstraZeneca, Bristol Myers Squibb, Janssen, Kite, Menarini, Oncopeptides, Pfizer, Regeneron, Roche, Sanofi, Takeda.

Sagar Lonial, MD, FACP, FASCO: consultant/advisor/speaker: AbbVie, Amgen, Bristol Myers Squibb, Genentech, GSK, Janssen, Novartis, Pfizer, Regeneron, Takeda; researcher: Bristol Myers Squibb, Janssen, Novartis, Takeda; individual publicly traded stock/stock options: TG Therapeutics.

Karthik Ramasamy, MD, PhD: consultant/advisor/speaker: AbbVie, Adaptive Biotech, Amgen, Bristol Myers Squibb (Celgene), GSK, Johnson & Johnson; researcher: Amgen, Bristol Myers Squibb (Celgene), GSK, Johnson & Johnson, Sanofi, Takeda, Pfizer; other financial or material support: GSK, Johnson & Johnson, Menarini, Stemline, Takeda.

Additional Disclosures

Generative artificial intelligence (AI) tools were used for revising or refining word-use for educational content. All AI-assisted content underwent human review, editing, and validation by qualified faculty and accredited education staff to ensure scientific accuracy, balance, and compliance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education.